| MAJOR REVIEW |
|
| Year : 2017 | Volume
: 29
| Issue : 1 | Page : 9-13 |
|
|
Update on hydroxychloroquine retinopathy
Remya Mareen Paulose1, Jay Chhablani2, Mahima Jhingan3
1 Little Flower Hospital and Research Center, Ernakulam, Kerala, India
2 Vitreo-Retina Services, L. V. Prasad Eye Institute, Hyderabad, Telangana, India
3 Vitreo-Retina Services, Aravind Eye Institute, Madurai, Tamil Nadu, India
Correspondence Address:
Remya Mareen Paulose
Little Flower Hospital and Research Center, Angamaly, Ernakulam, Kerala
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/kjo.kjo_29_17
|
|
|
Hydroxychloroquine (HCQ) in recent times has been used in treatment for a variety of autoimmune diseases and dermatological and rheumatological conditions. Retinal toxicity from HCQ and its analog chloroquine has been recognized for many years. Retinal toxicity secondary to HCQ is irreversible and can continue to progress even after cessation of therapy. Prompt screening and serial monitoring, with the utilization of imaging modalities, is of paramount importance to early detection.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
